Insider Selling: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) CEO Sells 18,700 Shares of Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) CEO Brian Goff sold 18,700 shares of the company's stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total value of $627,198.00. Following the sale, the chief executive officer now owns 105,401 shares in the company, valued at approximately $3,535,149.54. This represents a 15.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Agios Pharmaceuticals Stock Performance

AGIO traded down $0.18 during trading hours on Friday, reaching $33.47. The company's stock had a trading volume of 489,988 shares, compared to its average volume of 651,989. Agios Pharmaceuticals, Inc. has a 52 week low of $23.42 and a 52 week high of $62.58. The company's 50-day moving average is $31.27 and its 200-day moving average is $32.11. The firm has a market cap of $1.94 billion, a PE ratio of 2.98 and a beta of 0.73.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($1.55) EPS for the quarter, beating analysts' consensus estimates of ($1.80) by $0.25. Agios Pharmaceuticals had a negative return on equity of 2.75% and a net margin of 1,798.26%. The firm had revenue of $8.73 million for the quarter, compared to analyst estimates of $9.86 million. Equities analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Summit Investment Advisors Inc. grew its holdings in Agios Pharmaceuticals by 7.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 5,913 shares of the biopharmaceutical company's stock valued at $194,000 after buying an additional 394 shares in the last quarter. PNC Financial Services Group Inc. grew its holdings in Agios Pharmaceuticals by 16.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company's stock valued at $105,000 after buying an additional 499 shares in the last quarter. Federated Hermes Inc. grew its holdings in Agios Pharmaceuticals by 4.4% in the 4th quarter. Federated Hermes Inc. now owns 13,691 shares of the biopharmaceutical company's stock valued at $450,000 after buying an additional 582 shares in the last quarter. Alliancebernstein L.P. grew its holdings in Agios Pharmaceuticals by 1.2% in the 4th quarter. Alliancebernstein L.P. now owns 61,500 shares of the biopharmaceutical company's stock valued at $2,021,000 after buying an additional 708 shares in the last quarter. Finally, Atria Investments Inc grew its holdings in Agios Pharmaceuticals by 6.9% in the 4th quarter. Atria Investments Inc now owns 11,365 shares of the biopharmaceutical company's stock valued at $373,000 after buying an additional 737 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Scotiabank dropped their price target on Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a research note on Friday, May 2nd. Wall Street Zen cut Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday, May 19th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $58.60.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.